Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in developing countries. Many of the risk factors are well defined, but the underlying pathogenesis is not well understood. The demographics of the condition mirror those of the metabolic syndrome, with obesity and insulin resistance being the most commonly associated conditions. At present, therapy is aimed at correcting the risk factors, but there are no proven therapies at this point.
|Idioma original||English (US)|
|Número de páginas||3|
|Publicación||Expert Opinion on Emerging Drugs|
|Estado||Published - may 1 2005|
|Publicado de forma externa||Sí|
ASJC Scopus subject areas
- Pharmacology (medical)